Closed Loop Medicine is a technology company.
Closed Loop Medicine has raised $18.0M across 1 funding round.
Closed Loop Medicine has raised $18.0M in total across 1 funding round.
Closed Loop Medicine has raised $18.0M in total across 1 funding round.
Closed Loop Medicine's investors include Amadeus Capital Partners, Ananda Impact Ventures, Business Growth Fund, Downing Ventures, Parkwalk Advisors, Jonathan Milner.
Closed Loop Medicine is a HealthTech company founded in 2017 that develops prescription combination products integrating drugs, software, and devices to enable personalized medicine, particularly for chronic conditions like hypertension and insomnia[1][2][3]. It builds products such as CLM-HT01 for hypertension and CLM-IN01 for insomnia, serving patients, clinicians, pharmaceutical companies, payors, and healthcare providers by solving the limitations of one-size-fits-all dosing, which leads to suboptimal outcomes, higher costs, and adverse reactions[1][2][3]. The proprietary platform optimizes drug dosing through patient data from wearables and apps, delivering tailored care that improves efficacy, reduces side effects, and lowers healthcare costs, with $20.58M raised and positive clinical results announced as recently as 2024[2][3].
Closed Loop Medicine was incorporated on January 26, 2017, in the UK (initially as Closed Loop Pharma Ltd., renamed shortly after) by founder Paul Goldsmith, who brings expertise in healthcare innovation[3][4][5]. Headquartered in Cambridge at Babraham Research Campus, the idea emerged from recognizing flaws in traditional healthcare models—struggling with chronic disease management due to generic dosing—and the need for "closed loop" systems combining therapeutics, digital tools, and devices for patient-centric care[1][2][3]. Early traction included incubator/accelerator support, partnerships like with CPI and Queen Mary University London, and clinical advancements, such as the 2024 publication of hypertension study results in the Journal of the American Heart Association[2][3].
Closed Loop Medicine rides the personalized medicine trend, fueled by advances in wearables, AI analytics, and digital therapeutics amid rising chronic disease prevalence and healthcare cost pressures[1][2]. Timing aligns with regulatory shifts favoring combination products (drug + software as medical devices) and post-pandemic demand for remote, data-driven care, positioning it against competitors like DarioHealth and Lark Health[2][3]. Market forces—such as value-based care mandates and pharma's push for optimized therapies—favor its model, which creates new IP-protected revenue streams and influences ecosystems by partnering with providers and innovators to shift from disease-centric to individual-focused treatment[1][2].
Closed Loop Medicine is poised for expansion with its clinically validated platform, likely advancing more products beyond hypertension and insomnia into chronic diseases, leveraging recent funding and evidence to secure pharma partnerships and regulatory approvals[2][3]. Trends like AI-enhanced wearables, real-world evidence requirements, and global personalized medicine growth (projected to surge) will accelerate its trajectory, potentially evolving it into a key enabler of scalable, cost-effective care[1][2]. As healthcare systems prioritize outcomes over volume, its closed-loop innovations could redefine chronic disease management, delivering the personalized dosing promise that sparked its founding.
Closed Loop Medicine has raised $18.0M across 1 funding round. Most recently, it raised $18.0M Seed in November 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2021 | $18.0M Seed | Amadeus Capital Partners, Ananda Impact Ventures, Business Growth Fund, Downing Ventures, Parkwalk Advisors, Jonathan Milner |